TRACON PHARMS INC - TCON STOCK NEWS

TRACON Pharmaceuticals (TCON) has enrolled its 36th patient in the ENVASARC pivotal trial for envafolimab at 600 mg, allowing for an interim efficacy analysis by the independent data monitoring committee (IDMC). This analysis is set for Q4 2022, requiring one objective response in each cohort to continue patient accrual. The trial, launched in December 2020, targets advanced soft tissue sarcoma and anticipates full enrollment of 160 patients by the end of 2023. Envafolimab is a novel PD-L1 inhibitor approved in China for certain advanced solid tumors.

TRACON Pharmaceuticals (Nasdaq: TCON) announced that Charles Theuer, M.D., Ph.D., its President and CEO, will participate in a fireside chat at the Jefferies Healthcare Conference on June 10, 2022, at 11:00 am ET. The event aims to showcase TRACON's innovative cancer therapeutics and its CRO-independent development platform. Key products include Envafolimab, YH001, TRC102, and TJ004309, which target various types of cancer. For further details, visit TRACON's website.

TRACON Pharmaceuticals (TCON) announced that Charles Theuer, M.D., Ph.D., will present a corporate overview at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The presentation will be available on-demand starting at 7:00 AM ET on May 23, 2022, on the company's website. TRACON focuses on developing targeted cancer therapies and partners with life science companies through a unique product development platform. Their pipeline includes Envafolimab, YH001, TRC102, and TJ004309, aimed at various cancer treatments.

TRACON Pharmaceuticals (Nasdaq:TCON) reported its Q1 2022 financial results, highlighting a net loss of $9.5 million, up from $5.1 million in Q1 2021. Cash reserves decreased to $16.6 million as of March 31, 2022, from $24.1 million at year-end 2021. The company remains focused on advancing the ENVASARC trial with plans to deliver interim efficacy data later this year. TRACON is also preparing to initiate a Phase 1/2 trial of envafolimab combined with YH001 and doxorubicin. Additionally, arbitration outcomes for TJ4309 agreements are anticipated in the second half of 2022.

TRACON Pharmaceuticals (TCON) announced it will report its Q1 2022 financial and operating results after the market close on May 11, 2022. The company is focused on developing targeted cancer therapies using a cost-efficient, CRO-independent platform. It will also host a conference call to discuss these results and corporate activities. Key products in its pipeline include Envafolimab for sarcoma, YH001 for CTLA-4, TRC102 for lung cancer, and TJ004309 for advanced solid tumors. Interested parties can access the webcast through their website.

TRACON Pharmaceuticals (TCON) announced the successful approval of the amended ENVASARC protocol by the FDA and all 30 clinical sites, facilitating the enrollment of patients at a doubled dosage of envafolimab. Initial dosing began in March 2022, with over 10 patients already enrolled. Interim safety and efficacy reviews by the Independent Data Monitoring Committee (IDMC) are expected in the second half of 2022. The company aims to leverage its CRO-independent development platform to enhance cancer therapeutic innovations.

TRACON Pharmaceuticals (NASDAQ: TCON) announced that its CEO, Charles Theuer, will participate in a fireside chat at the Maxim Group 2022 Virtual Growth Conference on March 30, 2022, at 1:30 PM Eastern Time. This event will be hosted by Jason McCarthy and streamed live on M-Vest. TRACON focuses on developing targeted cancer therapies through a cost-efficient, CRO-independent platform. Its pipeline includes promising candidates like Envafolimab and YH001. Interested attendees can reserve their seats on M-Vest.

TRACON Pharmaceuticals (TCON) announced FDA approval of an amended protocol for its ENVASARC trial, aimed at treating refractory sarcoma. Dosing has been increased to 600 mg of envafolimab every three weeks after positive feedback from the Independent Data Monitoring Committee. The company expects to release interim efficacy data in the second half of 2022. In the fourth quarter of 2021, TRACON reported a net loss of $7.7 million and had $24.1 million in cash reserves. The company plans to start a combination trial with its CTLA-4 inhibitor YH001 later this year.

TRACON Pharmaceuticals (NASDAQ: TCON) announced that CEO Charles Theuer will present a corporate overview at the Oppenheimer 32nd Annual Healthcare Conference on March 16, 2022, at 4:00 PM ET. The company focuses on developing targeted cancer therapeutics through a capital-efficient platform and partnerships with ex-U.S. firms. Key products in its pipeline include Envafolimab for sarcoma and YH001, a CTLA-4 antibody. Interested parties can access the presentation via the TRACON website.